189 related articles for article (PubMed ID: 10593129)
1. New drugs for diabetes.
Tack CJ; Smits P
Neth J Med; 1999 Nov; 55(5):209-11. PubMed ID: 10593129
[No Abstract] [Full Text] [Related]
2. [Insulin analogs and new oral antidiabetic drugs].
Koivisto V
Duodecim; 1999; 115(20):2197-202. PubMed ID: 11973922
[No Abstract] [Full Text] [Related]
3. Preventing the progressive nature of type 2 diabetes.
Cardiovasc J S Afr; 2002; 13(4):211-3. PubMed ID: 12402899
[No Abstract] [Full Text] [Related]
4. Pharmacologic management of diabetes mellitus.
Mozersky RP
J Am Osteopath Assoc; 1999 Dec; 99(12 Suppl):S15-9. PubMed ID: 10659525
[TBL] [Abstract][Full Text] [Related]
5. Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al.
Baron MA
Diabetes Care; 2003 Dec; 26(12):3361-2; author reply 3362-3. PubMed ID: 14633839
[No Abstract] [Full Text] [Related]
6. Repaglinide in combination therapy.
Moses R
Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):33-8. PubMed ID: 12702006
[TBL] [Abstract][Full Text] [Related]
7. [Therapies for newly-onset diabetic patients].
Kawamori R
Nihon Rinsho; 2005 Feb; 63 Suppl 2():525-32. PubMed ID: 15779435
[No Abstract] [Full Text] [Related]
8. Combination therapy in type 2 diabetes: the role of repaglinide.
Moses R
J Assoc Physicians India; 2001 Jan; 49 Spec No():62-8. PubMed ID: 11235608
[No Abstract] [Full Text] [Related]
9. Type 2 diabetes management: a comprehensive clinical review of oral medications.
Quillen DM; Kuritzky L
Compr Ther; 2002; 28(1):50-61. PubMed ID: 11894443
[TBL] [Abstract][Full Text] [Related]
10. Managing type 2 diabetes. A look at the newer agents.
Larmore SS
JAAPA; 1999 Jun; 12(6):47-8, 51-4, 57. PubMed ID: 10728087
[No Abstract] [Full Text] [Related]
11. [Antidiabetic Drugs and the Kidney].
Candido R
G Ital Nefrol; 2016 Malattie Metaboliche e Rene; 33(S68):. PubMed ID: 27960013
[No Abstract] [Full Text] [Related]
12. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Kikuchi M
Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
[TBL] [Abstract][Full Text] [Related]
13. The use of insulin secretagogues in the treatment of type 2 diabetes.
Luna B; Hughes AT; Feinglos MN
Prim Care; 1999 Dec; 26(4):895-915. PubMed ID: 10523467
[TBL] [Abstract][Full Text] [Related]
14. Meglitinide analogues for type 2 diabetes mellitus.
Black C; Donnelly P; McIntyre L; Royle PL; Shepherd JP; Thomas S
Cochrane Database Syst Rev; 2007 Apr; 2007(2):CD004654. PubMed ID: 17443551
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
Inzucchi SE; Maggs DG; Spollett GR; Page SL; Rife FS; Walton V; Shulman GI
N Engl J Med; 1998 Mar; 338(13):867-72. PubMed ID: 9516221
[TBL] [Abstract][Full Text] [Related]
16. The rise and fall of troglitazone.
Bailey CJ
Diabet Med; 2000 Jun; 17(6):414-5. PubMed ID: 10975209
[No Abstract] [Full Text] [Related]
17. Post-load hyperglycaemia-an inappropriate therapeutic target.
Yudkin JS
Lancet; 2002 Jan; 359(9301):166-7. PubMed ID: 11809285
[No Abstract] [Full Text] [Related]
18. [symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
Drug Ther Bull; 2003 Jul; 41(7):52-4. PubMed ID: 12879789
[TBL] [Abstract][Full Text] [Related]
19. International Diabetes Federation meeting, 1997. Issues in the treatment of type 2 diabetes; sulfonylureas, metformin, and troglitazone.
Bloomgarden ZT
Diabetes Care; 1998 Jun; 21(6):1024-6. PubMed ID: 9614626
[No Abstract] [Full Text] [Related]
20. Troglitazone: a new class of oral antihyperglycemic for the treatment of type II diabetes.
Teter ML
Nurse Pract; 1997 Jul; 22(7):119-21. PubMed ID: 9253019
[No Abstract] [Full Text] [Related]
[Next] [New Search]